Expanded Lilly Diabetes Deal Plays To Yabao’s Ambitions
This article was originally published in PharmAsia News
After inking its second collaborative deal with Lilly for diabetes, Yabao sees the SGLT1 inhibitor from its US partner as appropriate for Asian patients and holding attractive potential in combination therapies. The Chinese firm says the new deal also fits well into its broader strategy of pursuing innovation and international partnerships.
Register for our free email digests: